These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 22378863)

  • 1. Detrimental effects of high-dose gonadotropin on outcome of IVF: making a case for gentle ovarian stimulation strategies.
    Kovacs P; Sajgo A; Kaali SG; Pal L
    Reprod Sci; 2012 Jul; 19(7):718-24. PubMed ID: 22378863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GnRH agonist versus GnRH antagonist in ovarian stimulation: the role of endometrial receptivity.
    Orvieto R; Meltzer S; Rabinson J; Zohav E; Anteby EY; Nahum R
    Fertil Steril; 2008 Oct; 90(4):1294-6. PubMed ID: 18178197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
    Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
    Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Impact of controlled ovarian hyperstimulation delayed, which occurs after functionally pituitary downregulation by depot GnRH agonist, on the outcome of in vitro fertilization and embryo transfer].
    Ma QH; Li SW; Huang ZY; Han ZY; Qiu DS; Han DW
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Nov; 38(6):980-3. PubMed ID: 18095601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does prolonged pituitary down-regulation with gonadotropin-releasing hormone agonist improve the live-birth rate in in vitro fertilization treatment?
    Ren J; Sha A; Han D; Li P; Geng J; Ma C
    Fertil Steril; 2014 Jul; 102(1):75-81. PubMed ID: 24746740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of poor responders: can outcomes be improved with a novel gonadotropin-releasing hormone antagonist/letrozole protocol?
    Schoolcraft WB; Surrey ES; Minjarez DA; Stevens JM; Gardner DK
    Fertil Steril; 2008 Jan; 89(1):151-6. PubMed ID: 17482177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical applications of different doses of leuprorelin acetate in in vitro fertilization-embryo transfer].
    Wang L; Zhang WX; Jiang H
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):910-4. PubMed ID: 23324190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential impact of controlled ovarian hyperstimulation on live birth rate in fresh versus frozen embryo transfer cycles: a Society for Assisted Reproductive Technology Clinic Outcome System study.
    Gerber RS; Fazzari M; Kappy M; Cohen A; Galperin S; Lieman H; Jindal S; Buyuk E
    Fertil Steril; 2020 Dec; 114(6):1225-1231. PubMed ID: 33012553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum progesterone level effects on the outcome of in vitro fertilization in patients with different ovarian response: an analysis of more than 10,000 cycles.
    Xu B; Li Z; Zhang H; Jin L; Li Y; Ai J; Zhu G
    Fertil Steril; 2012 Jun; 97(6):1321-7.e1-4. PubMed ID: 22494924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical outcome of patients with follicular development retardation by prolonged duration of gonadotropin administration for in vitro fertilization].
    Chen SL; Sun L; Kong LH; Li L; Li J; Zhu L; Gao TM; Xing FQ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Aug; 42(8):526-9. PubMed ID: 17983490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical application of gonadotropin-releasing hormone antagonist in Chinese women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer].
    Chen SL; Yin MN; Sun L; Li H; Chen X; Song HD; He JX; Zhu L; Xing FQ
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):588-90. PubMed ID: 17545062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do poor-responder patients benefit from increasing the daily gonadotropin dose during controlled ovarian hyperstimulation for IVF?
    Haas J; Zilberberg E; Machtinger R; Kedem A; Hourvitz A; Orvieto R
    Gynecol Endocrinol; 2015 Jan; 31(1):79-82. PubMed ID: 25223892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GnRH agonist versus GnRH antagonist in ovarian stimulation: the role of elevated peak serum progesterone levels.
    Orvieto R; Nahum R; Meltzer S; Liberty G; Anteby EY; Zohav E
    Gynecol Endocrinol; 2013 Sep; 29(9):843-5. PubMed ID: 23802563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endometrial thickness is related to miscarriage rate, but not to the estradiol concentration, in cycles down-regulated with gonadotropin-releasing hormone antagonist.
    Detti L; Yelian FD; Kruger ML; Diamond MP; Rode A; Mitwally MF; Puscheck EE
    Fertil Steril; 2008 Apr; 89(4):998-1001. PubMed ID: 17678904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
    Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
    Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended high dose letrozole regimen versus short low dose letrozole regimen as an adjuvant to gonadotropin releasing hormone antagonist protocol in poor responders undergoing IVF-ET.
    Fouda UM; Sayed AM
    Gynecol Endocrinol; 2011 Dec; 27(12):1018-22. PubMed ID: 21714697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High FSH dosing is associated with reduced live birth rate in fresh but not subsequent frozen embryo transfers.
    Munch EM; Sparks AE; Zimmerman MB; Van Voorhis BJ; Duran EH
    Hum Reprod; 2017 Jul; 32(7):1402-1409. PubMed ID: 28472321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of mild stimulation and conventional stimulation in ART outcome.
    Karimzadeh MA; Ahmadi S; Oskouian H; Rahmani E
    Arch Gynecol Obstet; 2010 Apr; 281(4):741-6. PubMed ID: 19834718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes from ovarian hyperstimulation following the sole administration of gonadotrophin-releasing hormone agonist in the context of in vitro fertilization: report of two cases and review of the literature.
    Pinto E; Pinelo S; Osório M; Ferreira C; Serra H; Pires I; Barbosa A; Figueiredo H; Felgueira E; Tavares A
    Gynecol Endocrinol; 2012 Jul; 28(7):545-8. PubMed ID: 22439899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of recombinant human follicle-stimulating hormone in improving oocyte quality in assisted reproductive techniques.
    Cheon KW; Byun HK; Yang KM; Song IO; Choi KH; Yoo KJ
    J Reprod Med; 2004 Sep; 49(9):733-8. PubMed ID: 15493565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.